National Bank of Canada
PLRX icon

National Bank of Canada’s Pliant Therapeutics PLRX Stock Holding History

National Bank of Canada’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$90 – 3150
2024
Q3 		$90 Hold
8
– – ﹤0.01% 2558
2024
Q2 		$86 Hold
8
– – ﹤0.01% 2638
2024
Q1 		$110 Hold
8
– – ﹤0.01% 2664
2023
Q4 		$143 Hold
8
– – ﹤0.01% 2648
2023
Q3 		$127 Hold
8
– – ﹤0.01% 2716
2023
Q2 		$145 Hold
8
– – ﹤0.01% 2676
2023
Q1 		$213 Hold
8
– – ﹤0.01% 2640
2022
Q4 		$155 Hold
8
– – ﹤0.01% 2710
2022
Q3 		$0 Hold
8
– – ﹤0.01% 2844
2022
Q2 		$0 Hold
8
– – ﹤0.01% 2944
2022
Q1 		$0 Hold
8
– – ﹤0.01% 2984
2021
Q4 		$0 Buy
+8
New +$127 ﹤0.01% 2836

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

National Bank of Canada's PLRX Position: Q4 2024 in Review

National Bank of Canada sold out of Pliant Therapeutics (PLRX) in Q4 2024, closing a stake of 8 shares — an estimated $90 sold.

National Bank of Canada first reported a position in PLRX in Q4 2021 and held it in 12 quarters. The position peaked at $213 in Q1 2023. 160 funds tracked by Wall St. Rank hold PLRX as of Q4 2024.

  • National Bank of Canada reported no remaining Pliant Therapeutics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 8 Pliant Therapeutics shares in Q4 2024, an estimated $90.
  • National Bank of Canada first reported a position in Pliant Therapeutics in Q4 2021 and held it in 12 quarters.
  • National Bank of Canada's Pliant Therapeutics position peaked at $213 in Q1 2023.
  • 160 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.